Secondary Logo

Journal Logo

June 2017 - Volume 42 - Issue 6
pp: 415-498,e281-e321

A Phase 1 Trial of Cabazitaxel Combined With 188Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial

van Dodewaard-de Jong, Joyce M.; Bouman-Wammes, Esther W.; Bloemendal, Haiko J.; More

Clinical Nuclear Medicine. 42(6):415-420, June 2017.

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment

Hamiditabar, Mohammadali; Ali, Muzammil; Roys, Joseph; More

Clinical Nuclear Medicine. 42(6):436-443, June 2017.

Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging

Schmuck, Sebastian; Mamach, Martin; Wilke, Florian; More

Clinical Nuclear Medicine. 42(6):e286-e293, June 2017.